news
Memory drug BPN14770 moves into Phase 1 safety trial
4 January 2016 | By Victoria White
BPN14770 may be a possible treatment for dementia and Alzheimer’s disease with less potential for side effects than rolipram...
List view / Grid view
Alzheimer’s disease
news
Enhancing proteasome activity may prevent dementia
22 December 2015 | By Victoria White
A study suggests that enhancing proteasome activity with drugs during the early stages of Alzheimer’s may prevent dementia and reduce damage to the brain...
news
IMI launches Calls to advance drug development in Ebola, Alzheimer’s and AMD
22 December 2015 | By Victoria White
The IMI has launched two Calls for proposals that will advance drug development in Ebola, childhood cancers, neurological disorders, and eye disease...
news
Harnessing antibiotic resistance to fight amyloid diseases
14 December 2015 | By Victoria White
A new study outlines a way of using antibiotic resistance to find chemicals capable of stopping amyloid formation in amyloid diseases such as Parkinson’s, Alzheimer’s and type II diabetes...
news
UNSW discovery could lead to new Alzheimer’s treatments
27 November 2015 | By Victoria White
Researchers have discovered how connections between brain cells are destroyed in the early stages of Alzheimer’s disease...
news
Presence of protein aggregates as important as form in cell death
19 November 2015 | By Victoria White
Scientists have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue...
news
Scientists use light to treat Alzheimer’s disease
16 November 2015 | By Victoria White
Scientists have conducted research to suppress an abnormal assembly of beta-amyloids by using photo-excited porphyrins...
news
Experimental Alzheimer’s drug J147 shows anti-aging effects
13 November 2015 | By Victoria White
Mice treated with J147 had better memory and cognition, healthier blood vessels in the brain and other improved physiological features...
news
Possible solution for Alzheimer’s immunotherapy side effect
6 November 2015 | By Victoria White
Scientists have discovered that small changes in anti-amyloid antibodies preserves the immunotherapeutic activity without the inflammatory side effects...
news
Researchers harness brain’s immune system to clear amyloid plaques
5 November 2015 | By Victoria White
The investigations were triggered when scientists observed that amyloid plaques were being cleared in mice with chronic brain inflammation...
news
Launch of Dementia Discovery Fund to deliver new dementia treatments by 2025
21 October 2015 | By Kate Douetil
This innovative new global investment fund has gained support from a wide variety of investors, including the UK Government’s Department of Health (DoH), Alzheimer’s Research UK and world-leading major pharmaceutical companies Biogen, GlaxoSmithKline, Johnson & Johnson, Lilly, Pfizer and Takeda...
news
Data on pGlu-3 Abeta antibody presented at Neuroscience 2015
19 October 2015 | By Victoria White
Pyroglutamate-3 Abeta (pGlu-3 Abeta), a post-translational modified Abeta, is a highly toxic Abeta variant which is abundant in brains of patients with Alzheimer’s disease...
news
GPR3 identified as a new target for Alzheimer’s disease treatment
15 October 2015 | By Victoria White
Researchers have determined that the protein GPR3 might play an important role in alleviating the cognitive deficits of 'amyloid plaques'...
news
Astex Pharmaceuticals joins The Dementia Consortium
12 October 2015 | By Victoria White
The Dementia Consortium is a £3.5m drug discovery collaboration between Alzheimer’s Research UK, MRC Technology, Eisai, Lilly and now Astex...
news
Cancer drug RGFP966 appears to sharpen memory
5 October 2015 | By Victoria White
Rats given RGFP966 were more attuned to what they were hearing and were able to retain and remember more information...
